Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Identify index funds with the lowest tax drag by examining turnover, fund composition, and distributions to optimize after-tax retirement growth.
27,308 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Bitcoin and XRP lead the 2026 debate on how to deploy $1,000 in crypto, with macro momentum and policy shifts potenti...
Investors are seeing a mining stock flying this week, led by SSR Mining. This piece breaks down the catalysts beyond ...
Investing hinges on leadership as much as numbers. This guide dives into how Josh D'Amaro's new approach could influe...
Rocket Lab faces a pivotal Q1 print this evening as analysts weigh Neutron timing against a record backlog. Guidance ...
This deep-dive breaks down Saga's Q1 2026 earnings, what the results mean for guidance, and how investors can score 2...
Greenboard closes a $15.5 million Series A to scale its AI-driven compliance platform, expanding to more banks and fi...
XRP steadies near key support and eyes a breakout above $1.60 this week. This week's ripple (xrp) price predicti...
When a top bank places a stock on its conviction list, it moves markets. This article explains why Goldman Sachs just...
A high-stakes aviation deal with China collides with a political stock move tied to a former president. Boeing and GE...
The CDC has expanded its Ebola response after the WHO declared an international public health emergency, deploying mo...
SoundHound AI trades in a fast-moving AI landscape with big growth potential and meaningful risks. This piece breaks ...